IRVINE, CA / ACCESSWIRE / February 22, 2017 / Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against PixarBio Corporation ("PixarBio" or the "Company") (OTC PINK: PXRB). Investors, who purchased or otherwise acquired PixarBio shares between October 31, 2016, and January 20, 2017, inclusive (the "Class Period"), are encouraged to contact the firm in advance of the March 27, 2017 lead plaintiff deadline.
If you purchased shares of PixarBio Corporation during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at firstname.lastname@example.org.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
On January 23, 2017, the SEC disclosed the indefinite suspension of trading in the securities of PixarBio "because the market for the security appears to reflect manipulative or deceptive activities and because of questions regarding the accuracy of assertions by PixarBio in press releases and its Form S-1 concerning, among other things: (1) the company's business combinations and current shareholders; (2) the identity and qualifications of key shareholders and employees; and (3) the company's current and prospective development efforts." When this information was announced to the public, the value of PixarBio fell, causing investors serious harm.
If you wish to learn more about this lawsuit, at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at email@example.com.
This press release may constitute Attorney Advertising in some jurisdictions.
Joon M. Khang, Esq.
SOURCE: Khang & Khang LLP